ADVIL LIQUI-GELS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADVIL LIQUI-GELS (ADVIL LIQUI-GELS).
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
| Metabolism | Primarily hepatic via CYP2C9, with minor pathways including glucuronidation and CYP2C8. Metabolites are inactive. |
| Excretion | Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%. |
| Half-life | 1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever. |
| Protein binding | Approximately 99% bound to albumin. |
| Volume of Distribution | 0.1 to 0.2 L/kg. Low Vd reflects extensive protein binding and limited tissue distribution. |
| Bioavailability | Oral bioavailability of ibuprofen from Liqui-Gels is approximately 85-90% due to first-pass metabolism. |
| Onset of Action | Oral (Liqui-Gels): 30 to 60 minutes. Faster absorption due to liquid-filled capsule. |
| Duration of Action | 4 to 6 hours. Duration is dose-dependent; single doses of 400 mg provide analgesia for up to 6 hours. |
| Molecular Weight | 206.28 |
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | eGFR 30–59 mL/min: maximum 800 mg/day in divided doses. eGFR <30 mL/min: contraindicated. |
| Liver impairment | Child-Pugh Class A: no adjustment. Class B: reduce dose by 50% and monitor. Class C: avoid use. |
| Pediatric use | Children ≥12 years: 200 mg orally every 4–6 hours, max 800 mg/day. Children <12 years: use weight-based ibuprofen (5–10 mg/kg/dose, max 40 mg/kg/day) not with Liqui-Gels formulation. |
| Geriatric use | Start at lowest effective dose; maximum 800 mg/day due to increased risk of GI and renal adverse effects. |
| 1st trimester | Risk of miscarriage and congenital malformations (especially cardiac and gastroschisis) associated with NSAID use; avoid if possible, especially after 20 weeks |
| 2nd trimester | May cause oligohydramnios and fetal renal impairment; avoid prolonged use |
| 3rd trimester | Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment |
Clinical note
Comprehensive clinical and safety monograph for ADVIL LIQUI-GELS (ADVIL LIQUI-GELS).
| Placental transfer | Ibuprofen crosses the placenta; cord blood concentrations are approximately 1-2% of maternal plasma levels. |
| Breastfeeding | Ibuprofen is excreted into breast milk in very low concentrations (less than 1% of maternal dose). Adverse effects in infants are rare, but monitor for gastrointestinal or renal effects. Considered compatible with breastfeeding by the American Academy of Pediatrics. |
■ FDA Black Box Warning
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Serious Effects |
History of allergic reaction (e.g., bronchospasm) to aspirin or other NSAIDsActive or history of gastrointestinal bleeding/perforationSevere heart failure (NYHA Class III-IV)Significant renal impairment (eGFR < 30 mL/min)Third trimester of pregnancyPerioperative pain in setting of coronary artery bypass graft (CABG) surgery
| Precautions | Increased risk of gastrointestinal adverse events including bleeding, ulceration, and perforation; use lowest effective dose for shortest duration; avoid in patients with advanced renal disease; may cause hypertension or worsening of pre-existing hypertension; caution in patients with asthma, coagulation disorders, or fluid retention. |
| Food/Dietary | Alcohol increases risk of GI bleeding. No specific food restrictions; however, taking with high-fat meals may delay absorption but reduces GI irritation. |
Loading safety data…
| Lactation Rating | L1 (Compatible) |
| Teratogenic Risk | First trimester: NSAIDs are associated with increased risk of miscarriage and cardiac defects. Second trimester: Generally considered safer; however, avoid prolonged use. Third trimester: Avoid due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal impairment. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and signs of bleeding. In third trimester, ultrasound for amniotic fluid index and ductus arteriosus flow if prolonged use. |
| Fertility Effects | NSAIDs may reversibly impair female fertility by inhibiting prostaglandin synthesis affecting ovulation. Use may delay time to conception. Effects are reversible upon discontinuation. |
| Clinical Pearls | Advil Liqui-Gels contain solubilized ibuprofen, allowing for faster absorption (onset ~20-30 min) compared to solid tablets. The liquid-filled gel capsule may cause more gastrointestinal distress in sensitive patients; administer with food. Avoid in patients with severe heart failure, history of GI bleed, or after coronary artery bypass grafting. Monitor renal function in elderly or dehydrated patients. Use lowest effective dose for shortest duration. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Do not exceed 1200 mg per day unless directed by a doctor. · Swallow whole; do not crush, chew, or break the capsule. · Avoid alcohol while taking this medication. · Stop and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (e.g., black/tarry stools). · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Do not take with other NSAIDs (e.g., aspirin, naproxen). |